Broad coverage extended to Japan and related regions
SAN JOSE, Calif.,
Jan. 23,
2024 /PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer, today announced that its collaborator,
Cleveland Clinic, has received a "Decision to Grant" notice from
the Japan Patent Office (JPO) for the patent application titled
"Ovarian Cancer Vaccines."
Anixa Chairman and CEO Dr. Amit
Kumar commented, "This new Japanese patent extends the
expanded claims for this novel ovarian cancer vaccine technology to
another geographic region, joining the European and U.S. patents
awarded last year. As the exclusive worldwide licensee of the
technology, we highly value the broad protection this patent
provides as our research and development continues. If our vaccine
is approved, one of the most aggressive gynecological cancers could
be prevented from ever developing in women globally."
The Ovarian Cancer Vaccines patent was invented by the late Dr.
Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic. The
researchers demonstrated in pre-clinical studies that vaccination
against the extracellular domain of anti-Müllerian hormone receptor
II (AMHR2-ED) significantly inhibits tumor growth and enhances
overall survival. The results indicate that vaccinating women
against AMHR2-ED could provide safe and effective preemptive
immunity against epithelial ovarian carcinoma, the most common form
of ovarian cancer.
Anixa is the exclusive worldwide licensee for the vaccine
technology from Cleveland Clinic, a nonprofit, multispecialty
academic medical center. Preclinical work on the vaccine is
supported by the National Cancer Institute's PREVENT Program, a
peer-reviewed program designed to support development of the best
ideas in cancer prevention.
About Anixa Bioscience's Ovarian Cancer
Vaccine
Anixa's ovarian cancer vaccine takes advantage of
endogenously produced proteins that have a function at certain
times in life, but then become "retired" and disappear from the
body. One such protein is the extracellular domain of
anti-Müllerian hormone receptor II (AMHR2-ED) which regulates
growth and development of egg-containing follicles in the ovaries
and is expressed throughout much of a woman's life, with expression
naturally and markedly declining during menopause, but which is
present in the majority of endothelian ovarian carcinomas.
Activating the immune system against this "retired" protein
provides preemptive immune protection against emerging ovarian
tumors that express AMHR2-ED. The vaccine also contains an adjuvant
that activates an innate immune response, which allows the immune
system to mount a response against emerging tumors to prevent them
from growing. This vaccine technology was invented by the late Dr.
Vincent Tuohy, who was the Mort and
Iris November Distinguished Chair in Innovative Breast Cancer
Research in the Department of Inflammation and Immunity at
Cleveland Clinic's Lerner Research Institute. Dr. Tuohy was
inventor of the technology, which Cleveland Clinic exclusively
licensed to Anixa Biosciences. He was entitled to a portion of the
commercialization revenues received by Cleveland Clinic and also
held equity in Anixa.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor T cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple
negative breast cancer
(TNBC), the most lethal form of the disease –
as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike
Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-japanese-patent-on-ovarian-cancer-vaccine-technology-302041596.html
SOURCE Anixa Biosciences, Inc.